ClinicalTrials.gg
WithdrawnNCT03986658Updated Nov 2, 2026

Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day

An interventional study of Linear Asymmetric rTMS System in Treatment Resistant Depression, sponsored by NeuroQore Inc.. Withdrawn at 1 site in Canada. Open to participants aged 15 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by NeuroQore Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.
Updated Nov 2, 2026Now WithdrawnStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
15 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada — 29 open to participants now, 36 under way, 7 of them phase 3. Depressive Disorder, Treatment-Resistant · Canada.

Enrollment
68th of 70
0 · median 50
Started
2025
with 10 others
No phase
33 of 76
12 open now
Registered
23rd of 76
by date

Among the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, this one is the 68th largest by enrollment of the 70 interventional ones that give a count, is one of 11 that started in 2025, is one of 33 with no phase, and was the 23rd registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

29 of the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 15 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, or all of them as a file.
02

Study summary

This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression (TRD). Conventional rTMS has been limited to sinusoidal biphasic electromagnetic pulses. In contrast, the First Dawn rTMS system by NeuroQore can sustain a repetitive linear asymmetric pulse. In addition, identification of rTMS treatment sites in adolescents with TRD most often relies on anatomic landmarks, but the First Dawn rTMS system utilizes personal fMRI data in a novel algorithm to determine where to apply the rTMS in each patient.

Based on adult data in healthy volunteers and patients with TRD, the investigators propose that the First Dawn rTMS system will be acceptable and well-tolerated by adolescents and will have minimal side effects. Please see https://clinicaltrials.gov/ct2/show/NCT02667041 for details on the completed pilot study in adults.

The investigators aim to investigate acceptability, tolerability, and side effects in groups of patients receiving treatment in numbers of sessions/day that are gradually accelerated over the course of the study. Results will be used to inform the development of a randomized controlled trial.

Read the detailed description

The 18 patients will be placed into 6 sub-groups sequentially as they are enrolled. All patients will receive a maximum of 30,000 pulses in their treatment course, as tolerated. The first group will receive daily sessions, similar to standard rTMS treatment. Each of the remaining groups will be set to receive more frequent sessions/day in decreasing numbers of days on a graduated schedule while holding the total number of pulses for each patient's treatment course at 30,000 pulses. in addition, the investigators will recruit one healthy volunteer to test fMRI server data transfer and analysis. This healthy volunteer will not receive rTMS.

Primary Objectives

The primary objectives of this study are to assess: 1) the feasibility of enrollment (number of patients who enroll divided by the number of patients approached), 2) study retention (number of patients completing the study divided by the number enrolled), and 3) AE/SE profile of the treatment at each protocol level and 4) patient experience in the study across the sample and within the sub-groups.

Secondary Objectives

The secondary objectives of this study are to: 1) evaluate daily changes in symptoms of depression and mental status; 2) evaluate fMRI changes in the LDLPFC after treatment; 3) evaluate post-treatment and 3-month changes in depression symptoms, global function, mental status, verbal memory.

03

Conditions studied

  • Treatment Resistant Depression

Keywords

  • Major Depressive Disorder
  • Repetitive Transcranial Magnetic Stimulation (rTMS)
  • Treatment-Resistant Depression
  • Adolescents
04

Who can participate

Ages eligible
15 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets criteria for MDD, as determined by a structured psychiatric interview.
  2. Meets criteria for TRD:

    1. failed two adequate courses of antidepressant medication OR
    2. failed adequate course of medication AND one course of psychotherapy.
  3. Score of > 40 on Child Depression Rating Scale-Revised OR score of > 20 on Child Depression Inventory-2.
  4. Fluent in speaking and reading English.

Exclusion criteria

Exclusion:

  1. Positive pregnancy test.
  2. Current or past: bipolar disorder, psychotic disorder, autism spectrum disorder, intellectual disability, substance use disorder, conduct disorder, as determined by a structured psychiatric interview.
  3. Medical illness that could lower the seizure threshold, e.g., epilepsy from any cause.
  4. Medications that could lower the seizure threshold or affect brain function.
  5. Psychotropic medications changed in two weeks prior to enrollment.
  6. Fails the TMS safety screening questionnaire.
  7. Fails fMRI screening process.
  8. Left-handed (may indicate different cortical lateralization which could affect outcomes).
  9. Involuntarily committed to the hospital.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Adolescents

    Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.

    Device: Linear Asymmetric rTMS System

Interventions

  • DeviceLinear Asymmetric rTMS System

    Linear Asymmetric rTMS System

06

What researchers measure

Primary outcomes

  1. Patient Enrollment Rate

    Number of patients who give consent divided by the number who are approached.

    Time frame: Through study completion, an average of 10 months

  2. Patient Completion Rate

    Number of patients who complete the study divided by the number of patients who enroll in the study.

    Time frame: Through study completion, an average of 10 months

  3. Side Effects Profile

    Measured with the rTMS Side Effect Questionnaire

    Time frame: Through study completion, an average of 10 months

  4. Patient Experience

    Measured with the Multi-Care Institute for Research and Innovation Research Participant Satisfaction Questionnaire

    Time frame: Through study completion, an average of 10 months

Secondary outcomes

  1. Change in self-reported MDD symptoms

    Measured with the Child Depression Inventory-2.(CDI-2)

    Time frame: Change from baseline score to score at 3 months

  2. Change in clinician-rated MDD symptoms

    Measured with the Child Depression Rating Scale-Revised (CDRS-R)

    Time frame: Change from baseline score to score at 3 months

  3. Change in function

    Measured with the Children's Global Assessment Scale (C-GAS)

    Time frame: Change from baseline score to score at 3 months

  4. Change in mental status

    Measured with the Mini-Mental State Examination (MMSE)

    Time frame: Change from baseline score to score at 3 months

  5. Change in short-term verbal memory

    Measured with the Hopkins Verbal Learning Test-Revised (HLVT-R)

    Time frame: Change from baseline score to score at 3 months

07

Study locations

1 site
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
08

References and documents

Individual participant data

Plan to share: No — clintrials.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for May 2025; primary completion for Oct 2028, 41 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Mar 2022 → May 2025, primary completion Oct 2022 → Oct 2028 and completion Dec 2022 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2019
First posted
Jun 14, 2019
StartEst.
May 2025was Mar 2022
Primary completionEst.
Oct 2028was Oct 2022
CompletionEst.
Dec 2029was Dec 2022
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.
changed Nov 2, 2026
Start date
Mar 2022→May 2025
Nov 2, 2026
Primary completion
Oct 2022→Oct 2028
Nov 2, 2026
Study completion
Dec 2022→Dec 2029
Nov 2, 2026
Enrollment
19 (estimated)→0 (actual)
Nov 2, 2026
Title
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Status unknown→Withdrawn
    Why stopped Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.
    Start date Mar 2022→May 2025
    Primary completion Oct 2022→Oct 2028
    Study completion Dec 2022→Dec 2029
    Enrollment 19 (estimated)→0 (actual)
    Title Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03986658
Lead sponsor
NeuroQore Inc.
Collaborators
Children's Hospital of Eastern Ontario
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
May 2025 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Kathleen Pajer, MD
principal investigator · Children's Hospital of Eastern Ontario (CHEO)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion